Publications by authors named "Gorm R Madsen"
Article Synopsis
- Recent data suggests a stable incidence of inflammatory bowel diseases (IBD) in Western countries, leading to a study on its occurrence and impact among newly diagnosed patients in Copenhagen from May 2021 to May 2023.
- A total of 554 patients were analyzed, revealing specific incidence rates: 23.4 for IBD overall, with ulcerative colitis (UC) at 14.0 and Crohn's disease (CD) at 8.6 per 100,000 person-years, and a shorter diagnostic delay for UC compared to CD.
- The study highlighted a significant disease burden, with high rates of disability, fatigue, and a need for advanced therapies shortly after diagnosis, particularly affecting those with Crohn's disease
Article Synopsis
- The study examined patient-reported outcomes (PROs) in individuals newly diagnosed with inflammatory bowel diseases (IBD), focusing on how these outcomes reflect treatment effectiveness and disease burden at diagnosis.
- A total of 319 patients (203 with ulcerative colitis and 116 with Crohn's disease) were assessed using various questionnaires to evaluate their quality of life and disease impact, revealing significant impairments in PROs, particularly among females and those with more extensive disease.
- Findings highlighted the high prevalence of symptoms like fatigue and abdominal pain in newly diagnosed IBD patients, emphasizing the need for ongoing PRO monitoring to better manage patient care and treatment strategies.
Background And Aims: Intestinal ultrasound has become a crucial tool for assessing inflammation in patients with inflammatory bowel disease, prompting a surge in demand for trained sonographers. While educational programs exist, the length of training needed to reach proficiency in correctly classifying inflammation remains unclear. Our study addresses this gap partly by exploring the learning curves associated with the deliberate practice of sonographic disease assessment, focusing on the key disease activity parameters of bowel wall thickness, bowel wall stratification, color Doppler signal, and inflammatory fat.
View Article and Find Full Text PDFArticle Synopsis
- Inflammatory bowel diseases (IBD) like Crohn's disease and ulcerative colitis are chronic conditions affecting the gastrointestinal tract, and a study has been launched in Denmark to explore their varied progression and treatment responses.
- The IBD Prognosis Study is a comprehensive, population-based research involving newly diagnosed IBD patients of all ages from a region covering around 1.05 million people, following strict diagnostic criteria for accurate identification.
- The study’s methods include regular clinical assessments, various imaging techniques, and systematic sample collection to analyze biomarkers, microbiome, and genetic information, alongside evaluating the impact of environmental factors and extraintestinal complications.
Background: Inflammatory bowel disease (IBD) and periodontitis are chronic, progressive, inflammatory diseases with similarly complex pathogeneses that involve an interplay between dysbiotic microbiota and dysregulated immune-inflammatory responses. However, whether the presence of periodontitis is associated with IBD activity and/or its severity remains unknown.
Methods: An online, questionnaire-based study was answered by 1093 patients with IBD, comprising 527 patients with Crohn's disease and 566 patients with ulcerative colitis.
Background: Intestinal ultrasound (IUS) is a non-invasive modality for monitoring disease activity in inflammatory bowel diseases (IBD). IUS training currently lacks well-defined standards and international consensus on competency criteria.
Aim: To achieve international consensus on what competencies should be expected from a newly certified IUS practitioner.
Introduction: Anti-SARS-CoV-2 vaccine clinical trials did not include patients with immune-mediated conditions such as inflammatory bowel disease [IBD]. We aimed to describe the implementation of anti-SARS-CoV-2 vaccination among IBD patients, patients' concerns, and the side effect profile of the anti-SARS-CoV-2 vaccines, using real-world data.
Methods: An anonymous web-based self-completed survey was distributed in 36 European countries between June and July 2021.
Article Synopsis
- Vedolizumab's effectiveness and safety were assessed in patients with ulcerative colitis (UC) and Crohn's disease (CD) who had never been treated with biological therapy (bio-naïve).
- The meta-analysis included 79 studies with over 8,000 bio-naïve patients, showing that 40% of UC patients and 54% of CD patients achieved clinical remission after 14 weeks, with better rates at 52 weeks.
- Bio-naïve UC patients showed a higher likelihood of achieving remission and a lower risk of serious adverse events compared to those previously exposed to biological treatments.
Introduction: N-benzylmethoxy (NBOMe) is a new class of hallucinogenic designer drugs sold on cheap blotter papers. They are potent 5-hydroxytryptamine-2A-receptor agonists, and since their recent entry into the drug market there have been worldwide reports of severe intoxications and even fatalities. This study reviews suspected NBOMe drug exposures reported to the Danish Poison Information Centre (DPIC).
View Article and Find Full Text PDF